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INTRODUCTION
The search of the ideal anesthetic agents started way 
back in the year 1957 when Woodbridge mentioned 
such criteria: motoric, sensory, autonomic as well 
as cognitive block. In 1950s Parke-Davis pharma-
ceutical company developed cyclohexylamines. 
Sernyl was the first agent to undergo clinical study; 
it was known as phencyclidine (PCP). Many stud-
ies, however, mentioned severe psychotomimetic 
effects of this drug in the study population. In the 
following era, 2(O-Chlorophenyl)-2-methylamino 
cyclohexanone or CI-581, identified as ketamine, 
was produced as the PCP derivative. Animal stud-
ies showed better results with this agent which 
generated anesthesia and analgesia effect similar to 
PCP with fewer side effects.1,2 
Unique properties and recent development in 
the areas of clinical properties of ketamine make 
this agent popular for a long time. This anesthetic 
agent has a wide range of indications. Many areas 
of clinical application of ketamine are explored in 
many studies. However, not many clinicians are 
familiar with the wide range of clinical applications 
of ketamine. 
Ketamine affects the central nervous system 
(CNS) to cause dose-dependent depression, which 
leads to a dissociative state, described as analgesia 
and amnesia without profound loss of conscious-
ness. The patients receiving ketamine seem to be 
unaware of the environment. The recovery time is 
dose-dependent and emergence is often accompa-
nied by psychotomimetic reactions (hallucinations, 
vivid dreams).3 
Ketamine has additional effects on the respi-
ratory system, which includes bronchodilation, 
minimal respiratory depression with only mild 
hypercapnia, and preserved protective airway 
reflexes. These effects are generally beneficial in 
comparison with other anesthetic agents. In the 
cardiovascular system, ketamine increases heart 
rate and blood pressure as well as increases pulmo-
nary artery pressure, especially in patients with 
preexisting heart disease. These may happen due 
to sympathetic stimulation, which creates a direct 
effect on the heart.3 
Ketamine consists of two optical enantiomers, 
R(-) and S(+), and the preservative benzethonium 
chloride. It has a relatively short distribution and 
elimination half-lives with a-elimination phase 
lasting a few minutes and the p-elimination half-
life lasting 2-3 hours.4 The contraindications of 
ketamine are uncontrolled arterial hypertension 
or hypersensitivity to the drug.3 Studies mentioned 
ketamine should be used with caution in patients 
with right heart failure and coronary artery disease.
MECHANISM OF ACTION
The effect of ketamine in CNS is a complex 
interaction of multiple binding sites, including 
N-methyl-D aspartate (NMDA) and non-NMDA 
glutamate receptors, nicotinic and muscarinic 
cholinergic, and monoaminergic and opioid 
receptors. Additionally, studies also mention the 
interaction with Na and L-type Ca channels. When 
Na channels are inhibited, this leads to a local anes-
thetic effect; where the blockage of Ca channel leads 
to cerebral vasodilation. The clinical properties of 
ketamine happen due to such interactions. The 
antagonistic effect of the NMDA receptor is respon-
sible for amnestic, psychotomimetic, analgesic, and 
neuroprotective effects of ketamine.3,4 
The NMDA receptor is classified as an iono-
tropic receptor, which is activated by glutamate, 
commonly found neurotransmitter in the NS. This 
ligand-gated ion channel is permeable to calcium, 
sodium, and potassium. The NMDA receptor 
requires glycine as its co-agonist and is hindered by 
magnesium. The NMDA receptor involves in the 
development of the pain pathway in chronic pain 
cases. Ketamine decreased stimulation in the CNS 
through the NMDA receptor. In the NMDA chan-
nel, phencyclidine receptor binds to ketamine and 
this inhibits activation of glutamate. However, the 
binding site of phencyclidine has some similarities 
with a binding site for magnesium.4 
In several cases, non-NMDA glutamate receptors 
may be activated by agonist quisqualate (AMPA) or 
kainate. In the past, these receptors were thought 
not to interact with ketamine. However, recent 
animal studies showed the contrary. This effect is 
facilitated through glutamate/NO/cGMP system. 
Non-NMDA receptor activation also stimulates 
NO synthesis so that this will increase the produc-
tion of intracellular cGMP. NO is well-known as its 
role as a peripheral and central neurotransmitter 
and pain reception. This may explain some of the 
ketamine profiles which were not explained by 
NMDA interaction.4 
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KETAMINE AND POSTOPERATIVE PAIN 
Postoperative pain remains as one of many undesir-
able complications for patients undergoing surgery. 
Many studies focus on the prevention and manage-
ment of postoperative pain. Delay of treatment 
may lead to poor outcomes. The analgesic effect of 
ketamine brings up the idea to utilize ketamine as 
an adjuvant to perioperative analgesia. Intravenous 
ketamine is proven to decrease postoperative pain 
up to 48 hours.5 Study showed that decreased pain 
intensity within the first 6 hours and this difference 
was statistically significant up to 48 hours postoper-
ative. The study also showed intravenous ketamine 
decreased 24 hours morphine consumption and 
delayed the first rescue dose.6 
In daily practice, both decreased pain intensity 
and opioid requirement are associated with a good 
analgesic profile. One study showed the average 
morphine consumption after major surgery was 
around 40 mg. The average morphine consump-
tion and the intensity of postoperative pain were 
reduced after the administration of intravenous 
ketamine.6 Therefore, decreased pain intensity 
after ketamine administration is linked with the 
opioid-sparing effect.
Even though morphine consumption was 
decreased after ketamine administration, the inci-
dence of morphine-related adverse effects did not 
change. This might happen because these studies 
did not evaluate the adverse effects specifically. 
Additionally, the decrease of morphine consump-
tion was not clinically significant to reduce the 
adverse effects.6 
Another study mentioned that ketamine was able 
to delay the administration of the first rescue dose. 
This result was statistically significant, but it was 
not significant clinically.7 However, this supported 
the efficacy of ketamine as an analgesic agent. The 
long-term effect of ketamine postoperatively was 
revealed in one study, which mentioned the bene-
ficial effect of ketamine for persistent pain around 
the surgical site up to 6 months postoperatively. 
This phenomenon was explained by the antagonist 
effect of ketamine at the NMDA receptor.7 
The role of ketamine exerts its role to modulate 
postoperative pain, both as standalone agent and as 
an adjuvant to other analgesics, such as fentanyl or 
morphine. The administration of caudal ketamine 
in pediatric patients was mentioned in some stud-
ies. The clinical trials concluded that ketamine 
might be used for caudal analgesia.6,7 
The important component to be discussed when 
administrating ketamine as a perioperative analge-
sic agent is harm. The risk of adverse effects, such as 
hallucinations, is the main reason why ketamine is 
unfavorable for some clinicians. Studies mentioned 
that consciousness of the patient and the use of 
benzodiazepines affected the risk of hallucinations 
after ketamine administration.8 However, benzo-
diazepines are not protective of hallucination. The 
study showed even after the administration of 
benzodiazepine premedication, some patients still 
suffered from hallucination following ketamine 
administration. Patients receiving ketamine should 
be informed with the side effects and must be 
monitored closely. 
KETAMINE AND PREEMPTIVE 
ANALGESIA
The analgesic profile of ketamine is profound even 
in small doses. This is beneficial to supplement local 
or regional anesthesia. Some studies mentioned that 
the administration of ketamine before any noxious 
stimuli is even more effective. This is known as 
preemptive analgesia. The purpose of preemptive 
analgesia is to diminish the development of pain 
pathway in the CNS. In the long term, this aims to 
reduce the postoperative analgesic requirements.9 
After the afferent nociceptive impulses arrive 
at the spinal cord, the CNS sensitization occurs. 
The receptor responsible for pain memory is the 
NMDA receptors. Therefore, NMDA antagonists 
may diminish the induction of central sensitiza-
tion and eradicate hypersensitivity. This leads to 
the prevention of pain. Currently, ketamine is the 
only NMDA antagonists approved by the Food and 
Drug Administration. Many studies have success-
fully established the efficacy of small dose ketamine 
as preemptive analgesia. Small doses of ketamine 
administered preemptively was shown to decrease 
opioid requirement in the postoperative period.8 In 
patients scheduled for cholelithiasis surgery who 
received ketamine 0.25 mg/kg IV preemptively, 
postoperative analgesic requirements decreased. 
Another study mentioned that administration of 
ketamine 0.5 mg/kg bolus before incision gener-
ated better pain control in comparison to those who 
received ketamine after wound closure.10 
Though timing and dosing differ between one 
study to another, overall administration of preemp-
tive ketamine decreases opioid use postoperatively. 
In average, opioid consumption was decreased up 
to 60% in comparison to those who did not receive 
ketamine. This was related to a lower incidence of 
opioid side effects. 
KETAMINE AND NEUROSURGERY
In the past ketamine was highly avoided in 
patients with increased intracranial pressure (ICP). 
However, recent studies discovered the neuropro-
tective role of ketamine. Racemic ketamine will 
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increase ICP, especially when the ICP is already 
increased and the IV dose of ketamine is more than 
1 mg/kg. This happens because increased arterial 
PCO2 because of ketamine-induced ventilator 
depression. Additionally, increased cerebral blood 
volume caused by increased arterial pressure also 
leads to increased ICP. However, the latest study 
showed 0.5-5 mg/kg ketamine did not increase ICP 
when ventilation was controlled (normocapnia).11 
Mild hyperventilation and benzodiazepines might 
contribute to ICP increase following ketamine 
administration. A study in patients with head injury 
showed there was no increase in ICP following 
ketamine administration when controlled ventila-
tion and adequate sedation were used.12 
Animal studies revealed increased cerebral 
blood flow (CBF) after administration of racemic 
ketamine and cerebral vasodilator N2O while 
decreased CBF was found after ketamine and barbi-
turates administration.13 This finding implies that 
the effect of ketamine in the cerebrovascular system 
is related to the former cerebrovascular tone. If 
ventilation is not controlled adequately, increased 
PCO2 may cause vasodilation. Nevertheless, ICP 
may still increase with normal PCO2. Increased 
cerebral metabolic rate after ketamine administra-
tion will increase CBF. 
Ketamine is showed to stimulate certain areas of 
the brain while inhibiting others. This is reflected by 
decreased CBF in areas with slow metabolism and 
increased CBF in high metabolism. Ketamine also 
affects the calcium channel so that it will increase 
blood flow through vasodilation. In general, race-
mic ketamine is related to increased CBF.12 
The effect of racemic ketamine on cerebral auto-
regulation is not yet evaluated. Ketamine was proven 
to prevent seizure activity by its antagonistic effect on 
NMDA. Hypoxia and ischemia will begin cascade, 
activated by both NMDA and non-NMDA recep-
tors, which leads to the membrane and cell destruc-
tion and neuronal death. When both receptors are 
stimulated by glutamate or aspartate, transmem-
brane flux and intracellular accumulation of sodium 
and calcium cause cell edema and activates cellular 
pathways. NMDA receptor antagonists are proven to 
be effective to prevent neuron degeneration; hence, it 
shows some neuroprotective profile.12,13 
Animal studies showed a large dose of ketamine 
bolus and followed by continue infusion reduced 
the neurological deficits due to hypoxia and isch-
emic insults.13 However, small bolus doses of 
ketamine after ischemia happened did not protect 
against neurological deficits. Another study 
mentioned that large dose of S(+) ketamine (1 mg/
kg/min) is related with decreased neurological defi-
cits, measured by plasma level of norepinephrine 
and dopamine, in comparison with a small dose 
(0.25 mg/kg/min).11
KETAMINE TO PREVENT OPIOID-
INDUCED ACUTE TOLERANCE
Amongst the known side effect of long-term and 
high-dose opioid use are hyperalgesia, depen-
dence, and tolerance. These are more pronounced 
in patients which experiences severe pain from 
malignancy, trauma, or neuropathy. Studies suggest 
that this may have to do with receptor desensitiza-
tion and loss of receptor function. Conformational 
changes in opioid receptor due to phosphoryla-
tion induced by agonist increases its affinity for 
cytosolic β-arrestins, which in turn redistributes 
opioid receptors from the plasma membrane to 
intracellular, in a process called opioid receptor 
internalization. Cells are also desensitized to opioid 
by functional uncoupling if the μ-opioid receptors 
by β-arrestin.14
All of these mentioned processes are 
 opioid-dependent. Painful stimuli may also 
produce opioid receptor internalization via NMDA 
receptor-mediated opioid release. This is where 
ketamine has a role. Pretreatment with NMDA 
receptor antagonists has been shown to inhibit 
μ-opioid receptor internalization in neurons caused 
by laparotomies in laboratory studies. Ketamine, in 
certain concentrations, interacts with phencycli-
dine (PCP)-binding site and inhibits NMDA recep-
tor activity. This suggests that ketamine inhibits 
opioid receptor internalization.14
Consistent with these findings, studies in the 
laboratory showed that in rats, fentanyl may 
produce both early and long-lasting hyperalgesia 
and acute tolerance to morphine; however, giving 
ketamine as a pretreatment completely abolished 
this effect.15 After intravenous administration, 
ketamine is metabolized into norketamine, which 
itself have antinociceptive action and enhance 
morphine’s antinociceptive action. Norketamin, 
therefore, may support opioid analgesia and prevent 
both hyperalgesia and tolerance.
KETAMINE IN MAJOR DEPRESSIVE 
DISORDER
Studies suggest that ketamine may produce a 
rapid-onset antidepressant effect in patients with 
major depressive disorder (MDD). This is benefi-
cial, especially given the fact that it may take weeks 
for the current pharmacologic treatment for MDD 
to be effective. Multiple studies have investigated 
this effect and found that the time to response was 
typically within hours. Administering ketamine in 
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rodent  models  produced  a  consistent  antidepres- 
sant effect.16
  The  reason  behind  this  remains  unclear,  but  it 
is speculated to involve several target sites, namely 
AMPA  receptor,  neurotrophins,  MTOR,  GSK-3, 
GABA,  and  others.  The  unpleasant  side  effect  of 
ketamine such as visual and auditory hallucinations, 
sedation and possible sleep disturbances, diarrhea, 
and impairment of certain types of memory, made 
it  unlikely  to  be  a  first-line  medication  for  MDD. 
However, these findings suggest a potential use of
ketamine as a rapid-onset antidepressant.17
CONCLUSIONS
As  time  passes  there  are  new  alternative  uses  of 
ketamine, a well-established anesthetic agent. S(+)
ketamine is associated with more potent and effec- 
tive anesthesia with decreased side effects compared 
to  racemic  ketamine.  The  analgesic  profile  of 
ketamine  is  explored  to  have  more  benefits,  such 
as  postoperative  pain  control  and  as  preemptive 
analgesia.  The  other  aspect,  which  has  been  stud- 
ied  extensively,  is  the  neuroprotective  profile  of 
ketamine.  The  administration  of  ketamine  is  not 
associated  with  increased  ICP  if  normocapnia  is 
achieved, making it possible anesthetic for neuro- 
surgery. The other areas to explore include the role 
of ketamine to prevent opioid-induced acute toler-
ance and treat a major depressive disorder.
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